Effects of diet, drugs, and genes on plasma fibrinogen levels

Annals of the New York Academy of Sciences

Volumn 936, Issue , 2001, Pages 509-521

  De Maat, Moniek P M ^a  

^a TNO   (Netherlands)

Author keywords

Diet effects; Drug effects; Gene effects; Plasma fibrinogen levels

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM ANTAGONIST; CIPROFIBRATE; DEFIBROTIDE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; FISH OIL; GEMFIBROZIL; LIPID; NABUMETONE; OMEGA 3 FATTY ACID; PECTIN; PENTOXIFYLLINE; PRAVASTATIN; PREDNISOLONE; STANOZOLOL; STATIN; TICLOPIDINE;

ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIET; DNA POLYMORPHISM; DRUG EFFECT; FIBRINOGEN BLOOD LEVEL; GARLIC; GENETIC VARIABILITY; HUMAN; SMOKING; TEA; THROMBOCYTE AGGREGATION;

EID: 0034964374     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03537.x     Document Type: Conference Paper

References (113)

1. Hæmostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
2. Fibrinogen and cardiovascular risk
3. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
4. The acute phase response
5. Fibrin gel structure and clotting time
6. Fibrin gel network characteristics and coronary heart disease: Relations to plasma fibrinogen concentration, acute phaes protein, serum lipoproteins and coronary atherosclerosis
7. The effect of fibrin structure on fibrinolysis
8. Substrate-bound fibrinogen, fibrin and other cell attachment- promoting proteins as a scaffold for cultured vascular smooth muscle cells
9. Determinants of plasma fibrinogen: Relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex. Results from the second MONICA Augsburg survey 1989-1990
10. Genetic and cultural inheritance of plasma fibrinogen concentration
11. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations
12. Segregation analysis of plasminogen activator inhibitor-1 and fibrinogen levels in the NHLBI family heart study
13. On the identification of beneficial and detrimental molecular forms of fibrinogen
14. Functional characterization of promoter elements involved in regulation of human B beta-fibrinogen expression. Evidence for binding of novel activator and repressor proteins
15. Fibrinogen fragments X, Y, D and E increase levels of plasma fibrinogen and liver mRNAs coding for fibrinogen polypeptides in rats
16. Influence of plasma triglyceride and plasma cholesterol levels on the clearance rate of fibrinogen
17. The effects of alcohol on coagulation and fibrinolytic factors: A controlled trial
18. Cardiovascular risk factors and alcohol consumption in France and Northern Ireland
19. Alcohol at moderate levels decreases fibrinogen expression in vivo and in vitro
20. Effect of moderate alcohol consumption on fibrinogen levels in healthy volunteers is discordant with effects on C-Reactive Protein
21. Diet, blood coagulation and fibrinolysis
22. Effect of green and black tea supplementation on lipids, lipid oxidation and fibrinogen in the hamster: Mechanisms for the epidemiological benefits of tea drinking
23. Tea drinking and hæmostasis: A randomized, placebo-controlled, crossover study in free-living subjects
24. Consumption of black and green tea has no effect on inflammation, hæmostasis and endothelial markers in smoking healthy individuals
25. Fatty acids, fibrinogen and blood flow: A general mechanism for hyperfibrinogenemia and its pathologic consequences
26. Free fatty acidemia as an inducer of systemic hyperfibrinogenemia and fibrinolytic inhibition
27. Hypercoagulability and reduced fibrinolysis in hyperlipidemia: Relationship to the metabolic cardiovascular syndrome
28. Fasting blood coagulation and fibrinolysis of young adults unchanged by reduction in dietary fat content
29. Effects of dietary fat modification on fibrinogen, factor VII, and plasminogen activator inhibitor-1 activity in subjects with impaired glucose tolerance
30. Lipid-lowering diets enriched with monounsaturated or polyunsaturated fatty acids but low in saturated fatty acids have similar effects on serum lipid concentrations in hyperlipidemic patients
31. Correlation between plasma fibrinogen and serum lipids in rats with hyperlipidemia induced by cholesterol free-high fructose or high cholesterol diet
32. Influence of n-6 versus n-3 polyunsaturated fatty acids in diets low in saturated fatty acids on plasma lipoproteins and hemostatic factors
33. Dietary fatty acids in human thrombosis and hemostasis
34. Fish consumption, omega-3 fatty acids and the Mediterranean diet
35. Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years
36. Fish oils and their possible role in the treatment of cardiovascular diseases
37. Associations of fish intake and dietary n-3 polyunsaturated fatty acids with a hypocoagulable profile. The Atherosclerosis Risk in Communities (ARIC) Study
38. The effects of fish oil on triglycerides, cholesterol, fibrinogen and malondialdehyde in humans supplemented with vitamin E
39. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris
40. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris
41. Drugs affecting plasma fibrinogen levels
42. Lowering the plasma fibrinogen concentration with drugs
43. Pharmacological approaches and strategies for therapeutic modulation of fibrinogen
44. Therapeutic interventions to lower plasma fibrinogen concentration
45. Drugs affecting plasma fibrinogen levels. Implications for new antithrombotic strategies
46. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia
47. Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients
48. Statins and fibrinogen
49. Lowering fibrinogen levels: Clinical update
50. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha
51. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia
52. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients
53. Linkage disequilibrium relationships among four polymorphisms within the human fibrinogen gene cluster
54. Association of genetic variation at the beta-fibrinogen gene locus and plasma fibrinogen levels; interaction between allele frequency of the G/A-455 polymorphism, age and smoking
55. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: The ECTIM study
56. The role of beta-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden
57. Fibrinogen plasma levels in an apparently healthy general population - Relation to environmental and genetic determinants
58. Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study
59. Elevated plasma fibrinogen - Cause or consequence of cardiovascular disease?
60. A common mutation (g(-455)→a) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease - A study of 9,127 individuals based on the Copenhagen city heart study
61. Beta-fibrinogen gene polymorphism (c-148→t) is associated with carotid atherosclerosis - Results of the Austrian stroke prevention study
62. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
63. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men. Proposed role for an acute-phase reaction pattern of fibrinogen
64. Bcl I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels - A case-control study in a sample of GISSI-2 patients
65. The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-(453)-A polymorphism of the beta-fibrinogen gene
66. Association between polymorphisms in the fibrinogen alpha- and beta-genes on the post-trauma fibrinogen increase
67. Positive association of the beta fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction
68. Detection of a complex that associates with the B beta fibrinogen G(-455)A polymorphism
69. The effect of genetic variation in the β-fibrinogen 5′-flanking region on nuclear protein binding, transcriptional activity and plasma fibrinogen level
70. Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice
71. Effect of genetic background and diet on plasma fibrinogen in mice. Possible relation with susceptibility for atherosclerosis
72. Effect of intensive glycaemic control on fibrinogen plasma concentrations in patients with Type II diabetes mellitus. Relation with beta-fibrinogen genotype
73. Effect of intensive glycemic control on fibrinogen plasma levels in diabetic subjects - Relationship with beta-fibrinogen genotype
74. Relation between dietary fiber consumption and fibrinogen and plasminogen activator inhibitor type 1: The national heart, lung, and blood institute family heart study
75. Dietary effects of circadian fluctuation in human blood coagulation factor VII and fibrinolysis
76. Nutritional status influences plasma fibrinogen concentration: Evidence from the THUSA survey
77. Moderate and large doses of ethanol differentially affect hepatic protein metabolism in humans
78. Epidemiology of fibrinogen
79. Inter-relationships between hæmostatic tests and the effects of some dietary determinants in the Caerphilly cohort of older men
80. Nutritional determinants of hæmostatic factors in the Caerphily Study
81. Prolonged very low calorie diet in highly obese subjects reduces plasma viscosity and red cell aggregation but not fibrinogen
82. Effect of a short-term very low calorie diet on plasma lipids, fibrinogen, and factor VII in obese subjects
83. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen - Effect of dieting with or without exercise in overweight postmenopausal women
84. The effect of diets, rich in monoor polyunsaturated fatty acids, on lipid metabolism and hæmostasis
85. Reduced plasma fibrinogen, serum peroxides, lipids, and apolipoproteins after a 3-week vegetarian diet
86. Hemostatic factors and blood lipids in young Buddhist vegetarians and omnivores
87. Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: Results from an in vitro and a dietary supplement study
88. Dietary pectin influences fibrin network structure in hypercholesterolaemic subjects
89. Possible mechanisms through which dietary pectin influences fibrin network architecture in hypercholesterolaemic subjects
90. The effect of ticlopidine on canine platelets, fibrinogen, and antithrombin III activity
91. Hemostaseologic and hematologic parameters with aspirin and ticlopidine treatment in patients with cerebrovascular disease: A cross-over study
92. Thrombolytic action of ticlopidine: Possible mechanisms
93. How does ticlopidine treatment lower plasma fibrinogen?
94. Lipid-hemostasis interactions: A new approach to cardiovascular risk factors
95. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects
96. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein a-1 in cultured cynomolgus monkey hepatocytes - Role of the peroxisome proliferator-activated receptor-alpha
97. Clinical pharmacokinetics of fibric acid derivatives (fibrates)
98. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients
99. Effect of ciprofibrate on fibrinogen synthesis in vitro on hepatoma cells and in vivo in genetically obese zucker rats
100. Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolaemia - A pilot, randomised, double-blind, dose-titrating study
101. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia
102. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia
103. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
104. Simvastatin in non-insulin-dependent diabetes mellitus: Effect on serum lipids, lipoproteins and hæmostatic measures
105. Influences of lipid-modifying agents on hemostasis
106. Effect of medication with pravastatin sodium on hemorheological parameters in patients with hyperlipoproteinemia
107. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia
108. Hypercoagulable state in patients with hypercholesterolemia: Effects of pravastatin
109. The effect of stanozolol on thrombotic risk factors in healthy individuals
110. The effect of aspirin on hæmostatic activity in the treatment of chronic venous leg ulceration
111. Short-term aspirin treatment does not reduce plasma fibrinogen concentration in young healthy adults
112. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study
113. Effect of plasma fibrinogen concentration on the inhibition of platelet aggregation after ticlopidine compared with aspirin